title: Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials.
abstract: Recombinant adeno-associated virus (rAAV) vectors are rapidly becoming the first choice for human gene therapy studies, as clinical efficacy has been demonstrated in several human trials and proof-of-concept data have been demonstrated for correction of many others. When moving into human use under the auspices of an FDA Investigational New Drug (IND) application, it is necessary to demonstrate the stability of vector material under various conditions of storage, dilution, and administration when used in humans. Limited data are currently available in the literature regarding vector compatibility and stability, leading most IND sponsors to repeat all necessary studies. The current study addresses this issue with an rAAV vector (rAAV1-CB-chAATmyc) containing AAV2-inverted terminal repeat sequences packaged into an AAV1 capsid. Aliquots of vector were exposed to a variety of temperatures, diluents, container constituents, and other environmental conditions, and its functional biological activity (after these various treatments) was assessed by measuring transgene expression after intramuscular injection in mice. rAAV was found to be remarkably stable at temperatures ranging from 4°C to 55°C (with only partial loss of potency after 20 min at 70°C), at pH ranging from 5.5 to 8.5, after contact with mouse or human serum (with or without complement depletion) or with gadolinium and after contact with glass, polystyrene, polyethylene, polypropylene, and stainless steel. The only exposure resulting in near-total loss of vector activity (10,000-fold loss) was UV exposure for 10 min. The stability of rAAV1 preparations bodes well for future dissemination of this therapeutic modality.
authors.affiliation: 1 Gene Therapy Center, University of Massachusetts Medical School , Worcester, MA 01655.
authors.forename: Alisha M
authors.initials: AM
authors.lastname: Gruntman
authors.forename: Lin
authors.initials: L
authors.lastname: Su
authors.forename: Qin
authors.initials: Q
authors.lastname: Su
authors.forename: Guangping
authors.initials: G
authors.lastname: Gao
authors.forename: Christian
authors.initials: C
authors.lastname: Mueller
authors.forename: Terence R
authors.initials: TR
authors.lastname: Flotte
mesh_terms: D000818:Animals; D036022:Capsid Proteins / Q000235:genetics / Q000378:metabolism; D000229:Dependovirus / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007273:Injections, Intramuscular; D051379:Mice; D011994:Recombinant Proteins / Q000235:genetics*; D020079:Terminal Repeat Sequences; D019076:Transgenes
chemical_list: D036022:Capsid Proteins; D011994:Recombinant Proteins
references.citation: Curr Protoc Microbiol. 2013;Chapter 14:Unit 14D.3
references.pmid: 23408131
references.citation: Hum Gene Ther. 2000 Mar 1;11(4):629-35
references.pmid: 10724041
references.citation: Invest Ophthalmol Vis Sci. 2015 Jan;56(1):526-37
references.pmid: 25537204
references.citation: Curr Protoc Microbiol. 2012 Aug;Chapter 14:Unit14D.1
references.pmid: 22875565
references.citation: N Engl J Med. 2011 Dec 22;365(25):2357-65
references.pmid: 22149959
references.citation: N Engl J Med. 2008 May 22;358(21):2231-9
references.pmid: 18441371
references.citation: Hum Gene Ther. 2008 Oct;19(10):979-90
references.pmid: 18774912
references.citation: N Engl J Med. 2014 Nov 20;371(21):1994-2004
references.pmid: 25409372
references.citation: Front Immunol. 2013 Oct 18;4:341
references.pmid: 24151496
references.citation: Mol Ther. 2012 Mar;20(3):590-600
references.pmid: 22252449
references.citation: N Engl J Med. 2008 May 22;358(21):2240-8
references.pmid: 18441370
references.citation: J Virol. 2013 Mar;87(6):2994-3002
references.pmid: 23269804
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15112-7
references.pmid: 18809924
references.citation: Hum Gene Ther. 2011 May;22(5):595-604
references.pmid: 21410419
references.citation: Curr Opin Biotechnol. 2002 Oct;13(5):418-23
references.pmid: 12459331